M L MacMillan

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Br J Haematol 157:732-41. 2012
  2. ncbi A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 109:2657-62. 2007
  3. ncbi Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program
    Margaret L Macmillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:16-22. 2008
  4. ncbi Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial
    M L MacMillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:447-54. 2009
  5. ncbi Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 113:2410-5. 2009
  6. ncbi Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies
    Margaret L Macmillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Semin Hematol 47:37-45. 2010
  7. ncbi Haematopoeitic cell transplantation for Fanconi anaemia - when and how?
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, 55455, USA
    Br J Haematol 149:14-21. 2010
  8. ncbi The best endpoint for acute GVHD treatment trials
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 115:5412-7. 2010
  9. ncbi Cellular therapy for fanconi anemia: the past, present, and future
    Margaret L Macmillan
    The Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 17:S109-14. 2011
  10. ncbi Hematopoietic cell transplantation for congenital bone marrow failure
    Margaret L Macmillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Curr Opin Oncol 17:106-13. 2005

Detail Information

Publications39

  1. ncbi What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Br J Haematol 157:732-41. 2012
    ..Patients with HR acute GVHD have a poor prognosis, require alternative initial therapy and should be the focus of novel therapeutic trials...
  2. ncbi A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 109:2657-62. 2007
    ..This prospective, multicenter, randomized clinical trial for steroid-resistant acute GVHD serves as a model for future evaluation of new agents...
  3. ncbi Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program
    Margaret L Macmillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:16-22. 2008
    ..Notably, this improvement over time was not observed in unmodified peripheral blood stem cell (PBSC) recipients, suggesting unmodified PBSC may not be the optimal stem cell source for children...
  4. ncbi Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial
    M L MacMillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:447-54. 2009
    ..This encouraging safety profile with haploidentical MSCs supports the investigation of unrelated 'off the shelf' allogeneic HLA-mismatched MSC products...
  5. ncbi Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 113:2410-5. 2009
    ..This study is registered at (http://www.clinicaltrials.gov) under the identifiers NCT00305682 and NCT00309842...
  6. ncbi Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies
    Margaret L Macmillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Semin Hematol 47:37-45. 2010
    ....
  7. ncbi Haematopoeitic cell transplantation for Fanconi anaemia - when and how?
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, 55455, USA
    Br J Haematol 149:14-21. 2010
    ..This paper will review the unique challenges of HCT in FA patients, with particular emphasis on the timing and approach to HCT...
  8. ncbi The best endpoint for acute GVHD treatment trials
    Margaret L Macmillan
    Blood and Marrow Transplant Program, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 115:5412-7. 2010
    ..No other differences in response by donor source were observed. These data suggest that day 28 is the best early endpoint for acute GVHD therapeutic trials in predicting 2-year TRM...
  9. ncbi Cellular therapy for fanconi anemia: the past, present, and future
    Margaret L Macmillan
    The Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 17:S109-14. 2011
    ....
  10. ncbi Hematopoietic cell transplantation for congenital bone marrow failure
    Margaret L Macmillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Curr Opin Oncol 17:106-13. 2005
    ..This review focuses on the outcome after allogeneic hematopoietic cell transplantation for the treatment of these disorders, with particular emphasis on recent discoveries and the challenges...
  11. ncbi Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease
    Margaret L Macmillan
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 8:40-6. 2002
    ..These data suggest that treatment with ATG can be an active therapy, especially in patients with skin GVHD and early signs of steroid resistance...
  12. ncbi High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, MMC 484, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Transplantation 76:1758-62. 2003
    ..Because IL-2 is a proinflammatory cytokine, we hypothesized that recipients with high-producer genotypes would have increased frequency of GVHD after allogeneic bone marrow transplantation (BMT)...
  13. ncbi Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation
    Margaret L Macmillan
    Pediatrics Department, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Br J Haematol 121:597-604. 2003
    ..2, P < 0.01) and decreased TRM (RR 0.1, P < 0.01). These data suggest that donor polymorphism in IL-1alpha and IL-1beta might influence survival after unrelated donor BMT, but does not alter risk of GVHD...
  14. ncbi Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
    ..Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care...
  15. ncbi Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation
    Poh-Lin Tan
    Department of Pediatrics, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 46:630-6. 2006
    ..9 years (range 1.9-4.8). CONCLUSIONS: In summary, a FLU-based, non-irradiation approach is effective for FA patients with AA undergoing HLA-identical sibling donor HCT...
  16. ncbi Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
    M Markova
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 39:193-9. 2007
    ..6 (95% CI 0.2-1.3) P=0.16) and with URD RR 0.4 (0.2-1.0) P=0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens...
  17. ncbi Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant
    A R Smith
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 46:368-71. 2011
    ..02), cGVHD (P=0.01) and development of PCT (P<0.01) were independently associated with less relapse. These data suggest that patients with PCT are at greater risk for GVHD, but at lower risk of leukemia relapse...
  18. ncbi Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis
    Catherine M Flynn
    Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Am J Hematol 82:867-72. 2007
    ..Advances in GVHD management and new approaches for relapsed or refractory disease are necessary to improve these outcomes...
  19. ncbi Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation
    L J Burns
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 30:945-51. 2002
    ....
  20. ncbi Chronic graft-versus-host disease: a prospective cohort study
    Mukta Arora
    Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 9:38-45. 2003
    ..Recognition of a high-risk group should facilitate assignment of more intensified regimens. Better treatment regimens need to be identified to improve survival and limit toxicity of prolonged immunosuppression...
  21. ncbi Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system
    Paul D Harker-Murray
    Pediatric Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 14:685-92. 2008
    ..These data support the use of allogeneic HCT in the treatment of children with poor prognosis isolated CNS relapse...
  22. ncbi Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis
    Satkiran S Grewal
    Department of Blood and Marrow Transplantation and the Center for Bioethics, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 103:1147-51. 2004
    ..The medical, legal, and ethical issues involved with this approach are discussed...
  23. ncbi Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia
    John E Wagner
    Division of Pediatric Hematology, Oncology, and Blood Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
    Blood 103:3226-9. 2004
    ..Our results suggest that BRCA2 testing should be considered in all patients with FA in whom the complementation group cannot be defined or in whom leukemia is diagnosed at or before 5 years of age...
  24. ncbi Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 8:387-94. 2002
    ..More effective prophylaxis and therapy for acute GVHD is needed for mismatched unrelated donor recipients and for those with severe GVHD...
  25. ncbi Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002
    ..7 x 10(5) CD34(+) cells per kilogram of recipient's body weight. Therefore, graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less...
  26. ncbi Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units
    Michael R Verneris
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 114:4293-9. 2009
    ..This trial was registered at http://clinicaltrials.gov as NCT00309842...
  27. ncbi Costs of pediatric allogeneic hematopoietic-cell transplantation
    Navneet S Majhail
    Adult Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Pediatr Blood Cancer 54:138-43. 2010
    ..Allogeneic hematopoietic-cell transplantation (HCT), although curative for some high-risk diseases, is a complex and costly procedure. The costs of transplantation among children have not been described previously...
  28. ncbi Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors
    Angela R Smith
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:1086-93. 2009
    ....
  29. ncbi Fatal hemorrhage from androgen-related hepatic adenoma after hematopoietic cell transplantation
    Ashish R Kumar
    Bone Marrow Transplant Program and Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA
    J Pediatr Hematol Oncol 26:16-8. 2004
    ..This case illustrates the need for extra vigilance in the detection and management of hepatic adenomas in patients treated with androgens, especially prior to HCT...
  30. ncbi Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source
    Juliet N Barker
    Division of Medical Hematology, Oncology, and Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 11:362-70. 2005
    ..These data suggest that the risk of serious infection after pediatric UCB transplantation is comparable to that with unmanipulated BM...
  31. ncbi Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia
    John E Wagner
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Blood 109:2256-62. 2007
    ....
  32. ncbi Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma
    Noel Laudi
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 11:129-35. 2005
    ....
  33. ncbi Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1065-72. 2006
    ..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL...
  34. ncbi Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics
    Adina M Cioc
    Department of Laboratory Medicine and Pathology, University of Minnesota Masonic Cancer Center, University of Minnesota Medical School, Minneapolis 55455, USA
    Am J Clin Pathol 133:92-100. 2010
    ..The data provide a rationale for integrating cytogenetic findings with independently evaluated morphologic findings for monitoring bone marrow status in FA...
  35. ncbi First phase insulin release and glucose tolerance in children with Fanconi anemia after hematopoietic cell transplantation
    Lynda E Polgreen
    Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Pediatr Blood Cancer 53:191-6. 2009
    ..Fanconi anemia (FA) is an autosomal and X-linked recessive disease of chromosomal instability, which results in bone marrow failure. Children with FA have been shown to have an increased risk of diabetes mellitus (DM)...
  36. ncbi Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy
    Margaret L Macmillan
    Department of Pediatrics, University of Minnesota, MMC 484, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA
    Am J Med 112:369-79. 2002
    ..Rates of yeast colonization after neutrophil recovery were similar in patients treated with fluconazole or clotrimazole...
  37. ncbi Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
    ..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
  38. ncbi Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation
    Sandra M P Cardoso
    Department of Pathology and Microbiology, University of Bristol, Homeopathic Hospital Site, Cotham, University Walk, Bristol BS8 1TD, UK
    Br J Haematol 126:704-10. 2004
    ..These data suggest that the IL-18 promoter GCG haplotype may influence survival after unrelated donor BMT without altering the risk of aGVHD...
  39. ncbi Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia
    Parinda A Mehta
    Division of Haematology Oncology, Cincinnati Children s Hospital and Medical Center, Cincinnati, OH 45229, USA
    Br J Haematol 137:152-7. 2007
    ..We did not observe an association with IL-1alpha genotype in donor and/or recipient and transplant-outcome. These data suggest that the outcome of unrelated donor transplant for CML is not influenced by IL-1alpha genotype...